mitomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics, nucleotoxic agents 1819 50-07-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mitomycin
  • mutamycin
  • Mitomycin C
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
  • Molecular weight: 334.33
  • Formula: C15H18N4O5
  • CLOGP: -0.80
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 146.89
  • ALOGS: -1.52
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.50 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma) 0.79 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
Aug. 24, 1981 FDA
Dec. 23, 2022 PMDA Kyowa Kirin Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 108.08 29.19 122 2018 674340 62812542
Pulmonary veno-occlusive disease 105.56 29.19 20 2120 1101 63485781
Conjunctival filtering bleb leak 97.52 29.19 11 2129 6 63486876
Haemolytic uraemic syndrome 84.09 29.19 19 2121 2484 63484398
Iris transillumination defect 69.59 29.19 10 2130 94 63486788
Scleral thinning 66.68 29.19 8 2132 13 63486869
Leukopenia 58.78 29.19 35 2105 77255 63409627
Scleromalacia 58.11 29.19 7 2133 12 63486870
Mucosal inflammation 57.11 29.19 29 2111 46899 63439983
Malignant neoplasm progression 56.82 29.19 35 2105 82086 63404796
Neutropenia 54.76 29.19 46 2094 174959 63311923
Thrombocytopenia 52.01 29.19 42 2098 151115 63335767
Bladder perforation 50.05 29.19 8 2132 160 63486722
Radiation skin injury 47.57 29.19 10 2130 933 63485949
Eye infection toxoplasmal 45.55 29.19 8 2132 287 63486595
Hypotony of eye 43.37 29.19 7 2133 149 63486733
Necrotising scleritis 43.33 29.19 7 2133 150 63486732
Tractional retinal detachment 42.73 29.19 6 2134 47 63486835
Pancytopenia 39.95 29.19 30 2110 96903 63389979
Extravasation 38.39 29.19 10 2130 2362 63484520
Rhegmatogenous retinal detachment 38.03 29.19 6 2134 110 63486772
Acute promyelocytic leukaemia 36.41 29.19 8 2132 919 63485963
Disease progression 31.75 29.19 29 2111 122729 63364153
Encapsulating peritoneal sclerosis 31.41 29.19 6 2134 344 63486538
Conjunctival erosion 30.45 29.19 5 2135 119 63486763
Metastases to liver 29.87 29.19 15 2125 23624 63463258
Thrombotic thrombocytopenic purpura 29.33 29.19 9 2131 3827 63483055

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 108.57 31.48 123 1800 419401 34535607
Conjunctival filtering bleb leak 83.41 31.48 10 1913 6 34955002
Bladder perforation 80.20 31.48 14 1909 292 34954716
Iris hypopigmentation 64.04 31.48 9 1914 40 34954968
Scleral thinning 57.34 31.48 7 1916 6 34955002
NPM1 gene mutation 55.55 31.48 9 1914 117 34954891
Bronchiolitis obliterans syndrome 51.13 31.48 9 1914 197 34954811
Chimerism 49.64 31.48 9 1914 234 34954774
Post embolisation syndrome 45.26 31.48 7 1916 66 34954942
Bladder necrosis 44.05 31.48 5 1918 0 34955008
Scrotal ulcer 37.70 31.48 8 1915 475 34954533
Gastric perforation 37.28 31.48 11 1912 2509 34952499
Hypotony of eye 35.30 31.48 6 1917 106 34954902
Eosinophilic cystitis 34.46 31.48 5 1918 29 34954979
Blood immunoglobulin G decreased 33.49 31.48 9 1914 1464 34953544
Dysuria 33.47 31.48 20 1903 27132 34927876

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Conjunctival filtering bleb leak 176.93 27.26 21 4084 12 79740271
Off label use 173.02 27.26 221 3884 906994 78833289
Scleral thinning 151.05 27.26 19 4086 29 79740254
Bladder perforation 126.36 27.26 21 4084 346 79739937
Hypotony of eye 111.87 27.26 18 4087 240 79740043
Scleromalacia 103.66 27.26 14 4091 47 79740236
Pulmonary veno-occlusive disease 100.42 27.26 22 4083 1626 79738657
Iris hypopigmentation 77.44 27.26 11 4094 58 79740225
Mucosal inflammation 74.22 27.26 47 4058 75533 79664750
Iris transillumination defect 68.26 27.26 11 4094 148 79740135
NPM1 gene mutation 62.37 27.26 10 4095 130 79740153
Encapsulating peritoneal sclerosis 61.07 27.26 13 4092 838 79739445
Haemolytic uraemic syndrome 60.83 27.26 18 4087 4431 79735852
Chimerism 54.89 27.26 10 4095 286 79739997
Radiation skin injury 54.32 27.26 13 4092 1421 79738862
Endophthalmitis 54.30 27.26 18 4087 6410 79733873
Neutropenia 53.91 27.26 70 4035 287640 79452643
Bronchiolitis obliterans syndrome 53.54 27.26 10 4095 329 79739954
Conjunctival erosion 52.30 27.26 9 4096 184 79740099
Post embolisation syndrome 51.73 27.26 8 4097 81 79740202
Extravasation 50.51 27.26 15 4090 3735 79736548
Eosinophilic cystitis 50.04 27.26 8 4097 102 79740181
Leukopenia 49.86 27.26 44 4061 116469 79623814
Gastric perforation 49.42 27.26 15 4090 4022 79736261
Thrombocytopenia 47.28 27.26 63 4042 265196 79475087
Bladder necrosis 45.46 27.26 6 4099 16 79740267
Necrotising scleritis 43.61 27.26 8 4097 238 79740045
Pupillary disorder 42.48 27.26 9 4096 567 79739716
Scrotal ulcer 39.15 27.26 8 4097 422 79739861
Blebitis 38.88 27.26 5 4100 10 79740273
Acute promyelocytic leukaemia 38.79 27.26 10 4095 1481 79738802
Visual acuity reduced 38.40 27.26 22 4083 29447 79710836
Eye infection toxoplasmal 37.16 27.26 8 4097 544 79739739
Pancytopenia 36.86 27.26 44 4061 165701 79574582
Conjunctival bleb 36.68 27.26 6 4099 89 79740194
Tractional retinal detachment 36.62 27.26 6 4099 90 79740193
Choroidal detachment 36.03 27.26 8 4097 628 79739655
Palmar-plantar erythrodysaesthesia syndrome 36.01 27.26 22 4083 33112 79707171
Chemical cystitis 35.50 27.26 4 4101 0 79740283
Acute myeloid leukaemia recurrent 34.79 27.26 11 4094 3372 79736911
Second primary malignancy 33.97 27.26 16 4089 14334 79725949
Rhegmatogenous retinal detachment 32.34 27.26 6 4099 190 79740093
Hepatic artery stenosis 32.22 27.26 6 4099 194 79740089
Dysuria 31.81 27.26 24 4081 50927 79689356
Blood immunoglobulin G decreased 30.62 27.26 10 4095 3399 79736884
Steroid diabetes 30.34 27.26 10 4095 3496 79736787
Anterior chamber pigmentation 30.21 27.26 4 4101 11 79740272
Disease progression 30.09 27.26 42 4063 184320 79555963
Corneal oedema 28.95 27.26 9 4096 2611 79737672
Hyphaema 28.15 27.26 7 4098 897 79739386

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01DC03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Other cytotoxic antibiotics
FDA MoA N0000000236 Alkylating Activity
FDA EPC N0000175558 Alkylating Drug
CHEBI has role CHEBI:35610 antineoplastic agents
MeSH PA D000477 Alkylating Agents
MeSH PA D000903 Antibiotics, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
MeSH PA D003432 Cross-Linking Reagents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D007202 Indicators and Reagents
MeSH PA D009676 Noxae
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Adenocarcinoma of pancreas indication 700423003 DOID:4074
Metastatic Gastric Cancer indication
Adjunct to incisional glaucoma surgery indication
Non-small cell lung cancer off-label use 254637007 DOID:3908
Malignant tumor of head and/or neck off-label use 255056009
Malignant tumor of anus off-label use 363490009 DOID:14110
Malignant tumor of urinary bladder off-label use 399326009 DOID:11054
Prevention of Recurrent Bladder Carcinoma off-label use
Corneal Conjunctival Intraepithelial Neoplasm off-label use
Stomatitis contraindication 61170000 DOID:9637
Acute infectious disease contraindication 63171007
Blood coagulation disorder contraindication 64779008 DOID:1247
Heart failure contraindication 84114007 DOID:6000
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Hemolytic uremic syndrome contraindication 111407006 DOID:12554
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Pulmonary Infiltrates contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.54 acidic
pKa2 10.39 Basic
pKa3 7.53 Basic
pKa4 4.95 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.2MG/VIAL MITOSOL MOBIUS THERAP N022572 Feb. 7, 2012 RX FOR SOLUTION TOPICAL 9539241 Jan. 2, 2028 MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY
0.2MG/VIAL MITOSOL MOBIUS THERAP N022572 Feb. 7, 2012 RX FOR SOLUTION TOPICAL 9649428 May 21, 2029 MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
40MG/VIAL JELMYTO UROGEN PHARMA N211728 April 15, 2020 RX POWDER PYELOCALYCEAL April 15, 2023 NEW PRODUCT
40MG/VIAL JELMYTO UROGEN PHARMA N211728 April 15, 2020 RX POWDER PYELOCALYCEAL April 15, 2027 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Indoleamine 2,3-dioxygenase 1 Enzyme Ki 4.60 CHEMBL

External reference:

IDSource
4018134 VUID
N0000146471 NUI
D00208 KEGG_DRUG
4018134 VANDF
C0002475 UMLSCUI
CHEBI:27504 CHEBI
CHEMBL105 ChEMBL_ID
D016685 MESH_DESCRIPTOR_UI
DB00305 DRUGBANK_ID
3043 INN_ID
50SG953SK6 UNII
5746 PUBCHEM_CID
204298 RXNORM
1274 MMSL
140168 MMSL
1973 MMSL
5122 MMSL
d00305 MMSL
002660 NDDF
387331000 SNOMEDCT_US
59240002 SNOMEDCT_US
7089 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9135 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 17 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9136 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 17 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9279 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 17 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9279 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 17 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9280 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 17 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9280 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 17 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-108 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-108 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-115 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-115 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-116 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-116 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-246 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-247 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-248 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 25021-250 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 19 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 25021-251 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 19 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 25021-252 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 19 sections
MITOMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 65219-564 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 15 sections
MITOMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 65219-566 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 15 sections
MITOMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 65219-568 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 15 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-518 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-519 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-520 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-995 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-996 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-997 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 68001-389 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 68001-390 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 68001-391 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 18 sections